文献速递免疫规划

四价脑膜炎球菌ACWY-破伤风类毒素结合疫苗(MenACWY-TT)在脾切除或脾功能低下儿童和青少年中的免疫原性和安全性:III期、开放、非随机研究结果

Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
PubMed 文献 · Vaccine · 2018-03-22

这项III期开放标签对照非随机研究纳入1-17岁脾功能受损儿童和青少年及年龄匹配健康对照,评估1剂和2剂MenACWY-TT的免疫原性和安全性。两组首剂后rSBA疫苗应答率92.5-100%、hSBA疫苗应答率55.6-77.1%,第二剂后所有参与者均有高应答;两组不良事件发生率相当,未报告疫苗相关严重不良事件。

要点

  • 脾功能受损组与健康对照组首剂MenACWY-TT后rSBA疫苗应答率均为92.5-100%。
  • 第二剂后两组rSBA和hSBA疫苗应答率均为73.0-100%。
  • 两组不良事件发生率相当,严重不良事件均与疫苗无关。

核心结论

  • 在这项描述性研究中,MenACWY-TT在脾功能受损儿童和青少年及健康对照中诱导相似的功能性和体液免疫应答,并具有临床可接受的安全性特征。

研究设计与样本

  • III期、开放标签、对照、非随机研究(NCT01641042),纳入1-17岁脾功能受损者(高危组)和年龄匹配健康对照(对照组)。
  • 免疫原性符合方案集每组40名参与者。

主要发现

  • 两组首剂MenACWY-TT后rSBA疫苗应答率为92.5-100%,hSBA疫苗应答率为55.6-77.1%。
  • 第二剂MenACWY-TT后所有参与者均有高应答,rSBA和hSBA疫苗应答率均为73.0-100%。
  • 两组各血清群rSBA和hSBA几何平均滴度较基线升高(幅度不同,但≥13.1倍)。
  • ≥84.4%的参与者多糖抗体浓度≥2.0 μg/ml,且两组间相似。
  • 高危组43名参与者中4名、对照组43名参与者中1名记录到严重不良事件(均与疫苗无关),未报告新发慢性疾病。

关键数值与推荐

  • 疫苗应答率定义为较接种前水平4倍升高或rSBA滴度≥1:32、hSBA滴度≥1:8。
  • 接种后4天和31天记录征集性和非征集性不良事件,整个研究期间记录严重不良事件和新发慢性疾病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals with functional or anatomic asplenia are at high risk for meningococcal disease. We evaluated the immunogenicity and safety of 1 and 2 doses of the quadrivalent meningococcal serogroups A, C, W, Y tetanus toxoid-conjugate vaccine (MenACWY-TT) in this high-risk population. METHODS: This phase III, open-label, controlled, non-randomized study (NCT01641042) enrolled 1-17-year-olds with impaired splenic activity (high-risk group) and age-matched healthy controls (control group). We measured immune responses to MenACWY-TT by serum bactericidal activity assays using rabbit (rSBA) and human (hSBA) complement and in terms of antibodies against polysaccharides of the 4 vaccine serogroups. We evaluated vaccine response rates (VRRs) as 4-fold increases from pre-vaccination levels or titers ≥1:32 (rSBA)/≥1:8 (hSBA). We recorded solicited and unsolicited adverse events (AEs) during 4 and 31 days post-vaccination, and serious AEs (SAEs) and new onset of chronic illnesses (NOCIs) throughout the study. RESULTS: The according-to-protocol cohort for immunogenicity included 40 participants per group. In both groups, the first MenACWY-TT dose induced rSBA VRRs of 92.5-100% and hSBA VRRs of 55.6-77.1% across vaccine serogroups. Following the second MenACWY-TT dose, all participants had high responses, with rSBA and hSBA VRRs of 73.0-100% across vaccine serogroups. rSBA and hSBA geometric mean titers for each serogroup increased in both groups (with different magnitudes, but ≥13.1-fold) compared with baseline levels. Polysaccharide antibody concentrations ≥2.0 μg/ml were detected in ≥84.4% of participants and were similar between groups. Incidences of solicited and unsolicited AEs were comparable between groups. We recorded SAEs in 4/43 participants in the high-risk group and 1/43 participants in the control group (none vaccine-related). No NOCIs were reported. CONCLUSION: In this descriptive study, MenACWY-TT induced similar functional and humoral immune responses and had a clinically acceptable safety profile in children and adolescents with impaired splenic activity and in healthy controls.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Klein NP, Habanec T, Kosina P, et al. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine. 2018. PMID: 29576307. doi:10.1016/j.vaccine.2018.02.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。